Congo Begins Ebola Vaccinations to Fight Country’s Worst Outbreak on Record, Health Minister Says
Health authorities are using 70,000 Ervebo doses in a trial and compassionate-use program to protect frontline workers and test cross-protection against Bundibugyo Ebola.
- On Thursday, Congo began vaccinating people against Ebola as Health Minister Roger Kamba officially launched the campaign in Kisangani, targeting frontline health workers and responders amid the country's deadliest outbreak on record.
- As of Tuesday, the Bundibugyo Ebola outbreak had recorded 5,713 confirmed cases and 2,744 deaths, spreading across six provinces including Ituri, North Kivu, and South Kivu. The disease remains out of control due to insecurity and population movements.
- The World Health Organization approved 70,000 doses of Ervebo for the campaign. Authorities allocated 50,000 doses for frontline workers, while 20,000 will support a clinical trial to study whether the vaccine protects against Bundibugyo.
- Although Ervebo is approved for Zaire ebolavirus, officials are using it under a compassionate-use program for Bundibugyo. Placide Mbala Kingebeni, Africa CDC's director for research and clinical trials, said data will be collected to measure vaccine efficacy.
- The World Health Organization warned the outbreak is on track to surpass the 2014-2016 West Africa Ebola crisis, which killed more than 11,000 people primarily in Guinea, Liberia, and Sierra Leone. Vaccination efforts aim to prevent health workers from carrying the virus into communities.
14 Articles
14 Articles
Congo begins Ebola vaccinations to fight country’s worst outbreak on record, health minister says
Congo has started vaccinating people against Ebola to combat its worst outbreak on record. The campaign launched Thursday in Kisangani, Tshopo province.
Fifth Ebola Vaccine Candidate Joins Race Against Congo Outbreak
Efforts to develop a vaccine against the strain of Ebola driving the deadly outbreak in Democratic Republic of Congo are expanding, with an experimental shot developed by an Egypt-based pharmaceutical company set to advance toward human testing.
The Egyptian pharmaceutical company Minapharm is about to advance to the human testing phase of an Ebola vaccine responsible for the deadly epidemic in the Democratic Republic of the Congo (DRCongo).
Coverage Details
Bias Distribution
- 55% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium



















